Hall Laurie J Trustee Boosts Stock Position in Danaher Co. (NYSE:DHR)

Hall Laurie J Trustee grew its holdings in Danaher Co. (NYSE:DHR) by 5.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,669 shares of the conglomerate’s stock after purchasing an additional 1,065 shares during the period. Danaher comprises approximately 1.6% of Hall Laurie J Trustee’s holdings, making the stock its 18th largest holding. Hall Laurie J Trustee’s holdings in Danaher were worth $4,974,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in DHR. Decker Retirement Planning Inc. bought a new position in shares of Danaher during the 4th quarter worth $31,000. Teachers Insurance & Annuity Association of America purchased a new position in Danaher during the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher in the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC bought a new position in shares of Danaher during the third quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC purchased a new position in Danaher during the third quarter valued at approximately $55,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Down 1.4 %

Shares of NYSE:DHR opened at $238.41 on Monday. The company has a market capitalization of $172.20 billion, a PE ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70. The business has a 50 day moving average of $234.85 and a two-hundred day moving average of $253.42. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm earned $2.02 EPS. As a group, analysts forecast that Danaher Co. will post 7.49 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analyst Ratings Changes

A number of analysts have weighed in on DHR shares. Barclays lowered their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Royal Bank of Canada decreased their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. UBS Group decreased their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Finally, Robert W. Baird cut their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.